Topic: non-small cell lung cancer
The startup posted initial clinical data that suggest MRTX849 can hold its own against Amgen’s rival cancer drug.
Merus reported that its investigational drug zenocutuzumab caused tumors to shrink in two patients with pancreatic cancer and one with lung cancer.
7. Thomas Lynch, Bristol-Myers Squibb
The RET inhibitor Eli Lilly picked up in its Loxo buyout continued to deliver, shrinking tumors in 56% of previously treated thyroid cancer patients.
In lung cancer, Amgen’s buzzy KRAS drug hit the heights. But in its latest update at ESMO over the weekend, it didn't follow suit in colon cancer.
Amgen unveiled data for the highest dose of its KRAS inhibitor, showing it kept cancer at bay in 100% of lung cancer patients.
Lilly has presented new data at the World Conference on Lung Cancer for its RET inhibitor LOXO-292 as it plots an NDA in the coming months.
The financing sets Achilles up to run human proof-of-concept studies of its personalized T-cell therapies in two types of solid tumors.
By profiling the metabolism of single tumor cells, researchers found they could predict treatment response among lung cancer patients.
Two months after announcing its KRAS inhibitor shrank lung tumors at ASCO, Amgen reported the drug did the same in colorectal and appendiceal cancers.